A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Meyerhardt, JeffreyGrady, Michele MLowe, Jamie NGargano, Michele AHuhn, Richard DBraun, Ada H2015-02-022014Meyerhardt, Jeffrey A, Michele M Grady, Jamie N Lowe, Michele A Gargano, Richard D Huhn, and Ada H Braun. 2014. “A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer.” Journal for Immunotherapy of Cancer 2 (Suppl 3): P71. doi:10.1186/2051-1426-2-S3-P71. http://dx.doi.org/10.1186/2051-1426-2-S3-P71.2051-1426http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890586en-USA Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancerOther2015-02-0210.1186/2051-1426-2-S3-P71